Synergistic anti-proliferative effects of gambogic acid with docetaxel in gastrointestinal cancer cell lines

BMC Complementary and Alternative Medicine

Volumn 12, Issue , 2012, Pages

  Zou, Zhengyun ^a   Xie, Li ^a   Wei, Jia ^a   Yu, Lixia ^a   Qian, Xiaoping ^a   Chen, Junhao ^a   Wang, Tingting ^a   Liu, Baorui ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; DOCETAXEL; FLUORESCEIN ISOTHIOCYANATE; GAMBOGIC ACID; LIPOCORTIN 5; MESSENGER RNA; PROPIDIUM IODIDE; SURVIVIN; TAU PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DIGESTIVE SYSTEM CANCER; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MONOTHERAPY; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84865305816     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-12-58     Document Type: Article

References (26)

1. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006, 12(3):354-362.
2. Parkin DM, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108. 10.3322/canjclin.55.2.74, 15761078.
3. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24(14):2137-2150. 10.1200/JCO.2005.05.2308, 16682732.
4. Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 2002, 168(11):597-608. 10.1080/11024150201680005, 12699095.
5. Ocvirk J, et al. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 2010, 16(25):3133-3143. 10.3748/wjg.v16.i25.3133, 2896750, 20593498.
6. Bokemeyer C, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27(5):663-671. 10.1200/JCO.2008.20.8397, 19114683.
7. Trudeau ME. Docetaxel: a review of its pharmacology and clinical activity. Can J Oncol 1996, 6(1):443-457.
8. Mavroudis D, et al. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. Am J Clin Oncol 2000, 23(4):341-344.
9. Einzig AI, et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996, 13(2):87-93. 10.1007/BF02993858, 9013471.
10. Ridwelski K, et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001, 12(1):47-51. 10.1023/A:1008328501128, 11249048.
11. Wang T, et al. Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells. Cancer Lett 2008, 262(2):214-222. 10.1016/j.canlet.2007.12.004, 18248784.
12. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
13. Bhat KM, Setaluri V. Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res 2007, 13(10):2849-2854. 10.1158/1078-0432.CCR-06-3040, 17504982.
14. Johnson ME, Howerth EW. Survivin: a bifunctional inhibitor of apoptosis protein. Vet Pathol 2004, 41(6):599-607. 10.1354/vp.41-6-599, 15557069.
15. Woll E, et al. Chemotherapy in gastric cancer. Anticancer Res 2008, 28(2):1213-1219.
16. Goyle S, Maraveyas A. Chemotherapy for colorectal cancer. Dig Surg 2005, 22(6):401-414. 10.1159/000091441, 16479107.
17. Sastre J, Garcia-Saenz JA, Diaz-Rubio E. Chemotherapy for gastric cancer. World J Gastroenterol 2006, 12(2):204-213.
18. Alisi A, Balsano C. Enhancing the efficacy of hepatocellular carcinoma chemotherapeutics with natural anticancer agents. Nutr Rev 2007, 65(12 Pt 1):550-553.
19. Geney R, Chen J, Ojima I. Recent advances in the new generation taxane anticancer agents. Med Chem 2005, 1(2):125-139.
20. Guo QL, et al. Gambogic acid inducing apoptosis in human gastric adenocarcinom SGC-7901 cells. Chin J Nat Med 2004, 2:107-110.
21. Liu W, et al. Anticancer effect and apoptosis induction of gambogic acid in human gastric cancer line BGC-823. World J Gastroenterol 2005, 11(24):3655-3659.
22. Wang J, et al. Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma. Toxicology 2009, 256(1-2):135-140.
23. Kawasaki H, et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 2001, 91(11):2026-2032. 10.1002/1097-0142(20010601)91:11<2026::AID-CNCR1228>3.0.CO;2-E, 11391581.
24. Zaffaroni N, Daidone MG. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat 2002, 5(2):65-72. 10.1016/S1368-7646(02)00049-3, 12135582.
25. Urano N, et al. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol 2006, 28(2):375-381.
26. Rouzier R, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 2005, 102(23):8315-8320. 10.1073/pnas.0408974102, 1149405, 15914550.